Table 5.

Rates of new damage in subgroups defined by past levels of disease activity by ethnicity

Percentage of Prior Months in:	Number of person-yearsobserved	Number of damage events	Rate of events per 10 person years	Rate Ratios(95% Confidence Intervals)	P-values
LLDAS - Caucasians
None	225	45	2.00	1.00 (Ref)
Not none, but < 25%	344	58	1.68	0.79 (0.49, 1.26)	0.32
25% to 50%	495	74	1.49	0.68 (0.45, 1.04)	0.075
50% to 75%	904	83	0.92	0.44 (0.29, 0.67)	0.0002
75%+	836	65	0.78	0.36 (0.23, 0.55)	<0.0001
Clinical Remission on Treatment1-Caucasians
None	576	116	2.01	1.00 (Ref)
Not none, but < 25%	832	90	1.08	0.51 (0.38, 0.70)	<0.0001
25% to 50%	734	65	0.88	0.44 (0.30, 0.62)	<0.0001
50% to 75%	485	40	0.82	0.40 (0.27, 0.61)	<0.0001
75%+	178	14	0.79	0.43 (0.24, 0.78)	0.0059
LLDAS – African-Americans
None	356	65	1.82	1.0 (Ref)
Not none, but < 25%	480	67	1.39	0.76 (0.54, 1.07)	0.13
25% to 50%	468	49	1.05	0.57 (0.39, 0.83)	0.0029
50% to 75%	528	45	0.85	0.46 (0.31, 0.68)	<0.0001
75%+	219	14	0.64	0.35 (0.19, 0.61)	0.0003
Clinical Remission on Treatment1–African-Americans
None	699	121	1.73	1.0 (Ref)
Not none, but < 25%	755	73	0.97	0.56 (0.41, 0.75)	0.0002
25% to 50%	375	31	0.83	0.47 (0.32, 0.70)	0.0002
50% to 75%	186	14	0.75	0.43 (0.20, 0.90)	0.026
75%+	36	1	0.28	0.16 (0.02, 1.18)	0.072

¹Requires Prednisone dose ≤ 5 mg/day, but allows for maintenance immunosuppressants and hydroxychloroquine.